Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop.
Hematology Am Soc Hematol Educ Program
; 2020(1): 57-66, 2020 12 04.
Article
em En
| MEDLINE
| ID: mdl-33275692
ABSTRACT
The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than 7+3 has been transformative. Despite the enthusiasm, however, the reality is that many patients are still frail and remain at risk for treatment-related complications. Translating the results of clinical trials into improved outcomes for these individuals requires an understanding of how best to manage the adverse effects of these agents. Which patients benefit most and what to watch for? When to stop therapy? Using illustrative case presentations, this review details the unique toxicities associated with each of the approved mutation-specific and nonspecific targeted drugs for AML. The goal of this review is to help clinicians determine the riskbenefit ratio in decision making for individual patients with AML.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Terapia de Alvo Molecular
/
Tomada de Decisão Clínica
/
Mutação
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Hematology Am Soc Hematol Educ Program
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article